These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 32822087)

  • 81. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats.
    Holmqvist S; Chutna O; Bousset L; Aldrin-Kirk P; Li W; Björklund T; Wang ZY; Roybon L; Melki R; Li JY
    Acta Neuropathol; 2014 Dec; 128(6):805-20. PubMed ID: 25296989
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Modification of the gut microbiome to combat neurodegeneration.
    Sasmita AO
    Rev Neurosci; 2019 Nov; 30(8):795-805. PubMed ID: 31095511
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Heterogeneity in gut microbiota drive polyphenol metabolism that influences α-synuclein misfolding and toxicity.
    Ho L; Zhao D; Ono K; Ruan K; Mogno I; Tsuji M; Carry E; Brathwaite J; Sims S; Frolinger T; Westfall S; Mazzola P; Wu Q; Hao K; Lloyd TE; Simon JE; Faith J; Pasinetti GM
    J Nutr Biochem; 2019 Feb; 64():170-181. PubMed ID: 30530257
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Parkinson's disease: 4 big questions.
    Deweerdt S
    Nature; 2016 Oct; 538(7626):S17. PubMed ID: 27783579
    [No Abstract]   [Full Text] [Related]  

  • 85. miR-let-7a suppresses α-Synuclein-induced microglia inflammation through targeting STAT3 in Parkinson's disease.
    Zhang J; Dongwei Zhou ; Zhang Z; Xinhui Qu ; Kunwang Bao ; Guohui Lu ; Jian Duan
    Biochem Biophys Res Commun; 2019 Nov; 519(4):740-746. PubMed ID: 31547989
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence.
    Pellegrini C; Antonioli L; Colucci R; Ballabeni V; Barocelli E; Bernardini N; Blandizzi C; Fornai M
    Parkinsonism Relat Disord; 2015 Dec; 21(12):1407-14. PubMed ID: 26499757
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Microbiome, Parkinson's Disease and Molecular Mimicry.
    Miraglia F; Colla E
    Cells; 2019 Mar; 8(3):. PubMed ID: 30866550
    [TBL] [Abstract][Full Text] [Related]  

  • 88. How gut microbes could drive brain disorders.
    Willyard C
    Nature; 2021 Feb; 590(7844):22-25. PubMed ID: 33536656
    [No Abstract]   [Full Text] [Related]  

  • 89. [Risk and course of COVID-19 in patients with Parkinson's disease].
    Zalyalova ZA; Khasanova DM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(9):152-156. PubMed ID: 34693704
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Cascading from SARS-CoV-2 to Parkinson's Disease through Protein-Protein Interactions.
    Estrada E
    Viruses; 2021 May; 13(5):. PubMed ID: 34066091
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Increasing Comparability and Utility of Gut Microbiome Studies in Parkinson's Disease: A Systematic Review.
    Boertien JM; Pereira PAB; Aho VTE; Scheperjans F
    J Parkinsons Dis; 2019; 9(s2):S297-S312. PubMed ID: 31498131
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
    Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
    Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
    [TBL] [Abstract][Full Text] [Related]  

  • 93. [Gastroparesis and other gastrointestinal symptoms in Parkinson's disease].
    Santos-Garcia D; de Deus T; Tejera-Perez C; Exposito-Ruiz I; Suarez-Castro E; Carpintero P; Macias-Arribi M
    Rev Neurol; 2015 Sep; 61(6):261-70. PubMed ID: 26350777
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Enteric alpha-synuclein pathology in LRRK2-G2019S Parkinson's disease.
    Rouaud T; Clairembault T; Coron E; Neunlist M; Anheim M; Derkinderen P
    Parkinsonism Relat Disord; 2017 Jul; 40():83-84. PubMed ID: 28483388
    [No Abstract]   [Full Text] [Related]  

  • 95. [Relationship between Drug Metabolism and Intestinal Microbiota in Parkinson's Disease].
    Hirayama M; Ohno K; Katsuno M
    Brain Nerve; 2020 Jul; 72(7):805-809. PubMed ID: 32641577
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF-α signaling pathway.
    Sun MF; Zhu YL; Zhou ZL; Jia XB; Xu YD; Yang Q; Cui C; Shen YQ
    Brain Behav Immun; 2018 May; 70():48-60. PubMed ID: 29471030
    [TBL] [Abstract][Full Text] [Related]  

  • 97. SARS-CoV-2 and the risk of Parkinson's disease: facts and fantasy.
    Merello M; Bhatia KP; Obeso JA
    Lancet Neurol; 2021 Feb; 20(2):94-95. PubMed ID: 33253627
    [No Abstract]   [Full Text] [Related]  

  • 98. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology.
    Braak H; de Vos RA; Bohl J; Del Tredici K
    Neurosci Lett; 2006 Mar; 396(1):67-72. PubMed ID: 16330147
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Introduction: The Gut-Brain Axis in Parkinson's Disease.
    van Laar T
    J Parkinsons Dis; 2019; 9(s2):S279. PubMed ID: 31683490
    [No Abstract]   [Full Text] [Related]  

  • 100. Probiotics for Parkinson's Disease.
    Gazerani P
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.